Tomato-derived lycopene shows modest real effects: lower upper blood pressure, more flexible arteries where already impaired, a small rise in protective cholesterol, and more sun tolerated before reddening. Isolated synthetic pigment fails. Population data favour lower cancer and death rates but remain unconfirmed. Harms are mostly cosmetic or digestive. Food has more support than capsules. (Full Review)

Protocol

Standard dose

10–30 mg daily

Tomato-derived, with food; the range covering most positive trials

Standardized tomato extract for blood pressure

Tomato-derived, not synthetic

The blood-pressure result belongs to standardized tomato extract, not isolated lycopene

Best time of day

Largest fat-containing meal

Typically lunch or dinner; absorption, not timing, governs the outcome

Time to effect

Artery function

4–12 weeks

Improves at 4 weeks, strengthens through 12

Blood pressure

4–8 weeks

Larger shift where pressure is already raised

Skin protection

8–12 weeks

Continuous intake; replaces no sunscreen

Benefits

High: Lower systolic blood pressure with standardized tomato extract; improved artery function; higher HDL cholesterol; reduced ultraviolet-induced skin redness and photodamage; symptom relief in precancerous mouth lesions

Medium: Lower fasting blood sugar in type 2 diabetes; lower cancer incidence and cancer mortality; lower all-cause and cardiovascular mortality; lower risk of fatty liver disease

Low: Improved sperm concentration; preserved cognitive function

Speculative: Lower circulating IGF-1; reduced oxidative DNA damage; delayed cellular senescence

Contraindications

Pregnant and breastfeeding women, at any gestational age, for supplemental doses above what food provides

Men with biopsy-confirmed multifocal high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation awaiting re-biopsy, at doses at or above 35 mg daily combined with selenium or green tea catechins

Known hypersensitivity to lycopene or to its food sources, particularly tomato

Active peptic ulcer disease or erosive reflux disease (Los Angeles Classification C or D), for acidic tomato-based preparations

Untreated fat malabsorption (pancreatic insufficiency, untreated coeliac disease, bile-duct obstruction)

Key Interactions

Lipase inhibitors (orlistat): caution

Bile acid sequestrants (cholestyramine, colestipol, colesevelam): caution

Cholesterol absorption inhibitors (ezetimibe): monitor

Statin plus niacin regimens: caution

Calcium-containing products (over-the-counter antacids, calcium supplements): monitor

Mineral oil laxatives and olestra-containing foods (over-the-counter): caution

Plant sterol and stanol supplements: caution

Beta-carotene, lutein and zeaxanthin supplements: monitor

Isolated soluble fibre supplements (pectin, psyllium, guar gum): monitor

Antihypertensive drugs (amlodipine, lisinopril, losartan, hydrochlorothiazide): caution

Blood-pressure-lowering supplements (beetroot nitrate, garlic extract, hibiscus, magnesium): caution

Cytotoxic chemotherapy and radiotherapy: caution

Risk & Side Effects

Medium: More prostate cancers detected in men with precancerous prostate lesions

Low: Preterm labour and low birth weight in pregnancy; orange-yellow skin discolouration; gastrointestinal upset and reflux; hypersensitivity to tomato-derived extracts

Speculative: Pro-oxidant behaviour at high concentrations; displacement of other carotenoids

Monitoring

Marker	Target	Why
Serum lycopene	0.6–1.2 µmol/L (roughly 32–64 µg/dL)	Confirms absorption and adherence
Blood pressure, seated and averaged	Below 120/80 mmHg	The most responsive endpoint
HDL cholesterol	Above 60 mg/dL (1.55 mmol/L)	Lipid fraction most consistently moved
Triglycerides	Below 80 mg/dL	No change in pooled trials; a rise points to diet or alcohol
Fasting glucose and HbA1c	Glucose 75–86 mg/dL; HbA1c 4.8–5.4%	Glucose signal is largest in impaired control
hs-CRP	Below 0.5 mg/L	Tracks the proposed inflammatory pathway
ALT	10–26 U/L in men, 8–22 U/L in women	Liver strain and the fatty-liver association
PSA, men from age 45	Below 1.0 ng/mL at 40–49 and 1.5 ng/mL at 50–59; year-on-year rise under 0.35 ng/mL	Not reliably lowered, so a rise is not attributable to the supplement
Skin carotenoid score by reflection spectroscopy	No established target; change from the individual's own baseline	Non-invasive adherence check between blood draws

Cadence: 4 weeks for absorption and tolerance; 12 weeks for blood pressure, lipids and glucose; then every 6–12 months on a stable dose, with PSA at 6–12 months and annually thereafter in men

Qualitative Assessment

Skin response to sun — whether the redness threshold shifts after 8–12 weeks
Skin tone and texture — hydration and evenness; orange discolouration on palms, soles and nasal folds
Exercise tolerance and recovery — stamina changes consistent with better artery function
Gastrointestinal comfort — reflux, bloating or loose stools appearing after dosing
Mouth comfort where precancerous lesions are treated — pain, burning, mouth opening

Lycopene for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment